Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05658575 · ClinicalTrials.gov registry record · Phase 2
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
A Phase 2 study of Arthritis and Gout, sponsored by Olatec Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT05658575 is a Phase 2 study of Arthritis and Gout that is actively recruiting participants, run by Olatec Therapeutics. The registered enrollment target is 300 participants, below the 4,504-participant average among 48 other Arthritis trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05658575, a Phase 2 study of Arthritis and Gout, is actively recruiting participants, sponsored by Olatec Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
Conditions Studied
Interventions
- DRUG Dapansutrile
- OTHER Placebo Tablet
Study Locations (20)
Florida
- Hillcrest Medical Research - DeLand
- SIMEDHealth - Gainesville
- University of Florida Health Jacksonville - Jacksonville
- Well Pharma Medical Research - Miami
- Clinical Research of West Florida - Tampa
California
- American Institute of Research - Los Angeles
- TriWest Research Associates - San Diego
- Valiance Clinical Research - Tarzana - Tarzana
Arizona
- Arizona Arthritis & Rheumatology Associates - Glendale - Glendale
- Arizona Arthritis & Rheumatology Associates (AARA), P.C. - Mesa - Mesa
Illinois
- Great Lakes Clinical Trials - Chicago
- Advanced Quality Medical Research - Orland Park
New York
- NYU Langone - New York
- IMA Clinical Research - Manhattan - New York
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Arthritis Center of North Georgia - Gainesville - Gainesville
Kentucky
- The Research Group of Lexington - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-01-06 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05658575
The ClinicalTrials.gov registry entry for NCT05658575 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,504-participant average among 48 other Arthritis trials with a reported enrollment target (93% lower). The listed sponsor is Olatec Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Dapansutrile is the first listed.
NCT05658575 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05658575 about?
NCT05658575 is a clinical study titled "Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare". The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
What is the current status of trial NCT05658575?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2023-01-06. Estimated completion is 2027-01-31.
What conditions does trial NCT05658575 study?
This clinical trial studies the following conditions: Arthritis, Gout, Joint Pain, Gout Flare, Acute Gout Flare.
What interventions are being tested in trial NCT05658575?
The interventions under investigation include: Dapansutrile (DRUG), Placebo Tablet (OTHER).
Who is sponsoring clinical trial NCT05658575?
This trial is sponsored by Olatec Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05658575 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultralow Dose PET Imaging for 18F-NaF Uptake
RECRUITING · Phase 2
-
Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis
RECRUITING · Phase 2
-
Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis
COMPLETED · Phase 2
-
Fitness and Exercise for People With Arthritis
COMPLETED · Phase 2
-
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
COMPLETED · Phase 2
-
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.